Precision Supplemental Imaging in Women With Dense Breasts
NCT: NCT07277738 · NOT_YET_RECRUITING
Brief Summary
Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.
Frequently Asked Questions
What is Precision Supplemental Imaging in Women With Dense Breasts?
Precision Supplemental Imaging in Women With Dense Breasts is a clinical trial registered under NCT07277738. Current status: NOT_YET_RECRUITING.
What is the status of NCT07277738?
The current status of NCT07277738 (Precision Supplemental Imaging in Women With Dense Breasts) is: NOT_YET_RECRUITING.
When did Precision Supplemental Imaging in Women With Dense Breasts start?
Precision Supplemental Imaging in Women With Dense Breasts started on 2026-06-30.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.